[go: up one dir, main page]

MX2020004552A - Vacuna potenciadora de celulas t. - Google Patents

Vacuna potenciadora de celulas t.

Info

Publication number
MX2020004552A
MX2020004552A MX2020004552A MX2020004552A MX2020004552A MX 2020004552 A MX2020004552 A MX 2020004552A MX 2020004552 A MX2020004552 A MX 2020004552A MX 2020004552 A MX2020004552 A MX 2020004552A MX 2020004552 A MX2020004552 A MX 2020004552A
Authority
MX
Mexico
Prior art keywords
polypeptides
polynucleotides
vectors
antigens
invariant chain
Prior art date
Application number
MX2020004552A
Other languages
English (en)
Inventor
Alfredo Nicosia
Elisa Scarselli
Antonella Folgori
Armin Lahm
Original Assignee
Nouscom Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom Ag filed Critical Nouscom Ag
Publication of MX2020004552A publication Critical patent/MX2020004552A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a polipéptidos que comprenden un fragmento de una cadena invariante de teleósteo fusionada a uno o más antígenos o una cadena invariante de teleósteo fusionada a uno o más antígenos o fragmentos antigénicos de los mismos, un polinucleótido que codifica dichos polipéptidos, vectores que comprenden dichos polinucleótidos, una colección de vectores que comprenden dichos polinucleótidos y el uso de dichos polipéptidos, polinucleótidos, vectores para tratar o prevenir enfermedades, en particular enfermedades tumorales. Los polipéptidos de cadena invariante de teleósteo o fragmentos de los mismos actúan como "potenciadores de células T" que convierten secuencias antigénicas no inmunogénicas en antígenos de células T inmunogénicos.
MX2020004552A 2017-11-03 2018-11-02 Vacuna potenciadora de celulas t. MX2020004552A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17200036 2017-11-03
EP17211235 2017-12-29
PCT/EP2018/080027 WO2019086615A1 (en) 2017-11-03 2018-11-02 Vaccine t cell enhancer

Publications (1)

Publication Number Publication Date
MX2020004552A true MX2020004552A (es) 2020-10-07

Family

ID=64332267

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004552A MX2020004552A (es) 2017-11-03 2018-11-02 Vacuna potenciadora de celulas t.

Country Status (12)

Country Link
US (1) US11912743B2 (es)
EP (1) EP3703744A1 (es)
JP (2) JP7386537B2 (es)
KR (1) KR102747530B1 (es)
CN (1) CN111670046B (es)
AU (1) AU2018358019B2 (es)
BR (1) BR112020008308A2 (es)
CA (1) CA3078692A1 (es)
IL (1) IL274409B2 (es)
MX (1) MX2020004552A (es)
SG (1) SG11202003799RA (es)
WO (1) WO2019086615A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020079234A1 (en) * 2018-10-19 2020-04-23 Nouscom Ag Teleost invariant chain cancer vaccine
AU2019379306B2 (en) * 2018-11-15 2025-03-06 Nouscom Ag Selection of cancer mutations for generation of a personalized cancer vaccine
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US12018289B2 (en) 2019-11-18 2024-06-25 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
EP4135757A1 (en) * 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
JP2025500867A (ja) * 2021-12-16 2025-01-15 ヤンセン バイオテツク，インコーポレーテツド 前立腺癌ワクチン及びその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2880060C (en) 2004-01-23 2018-03-13 Agostino Cirillo Chimpanzee adenovirus vaccine carriers
JP2012509071A (ja) 2008-11-21 2012-04-19 ケベンハウン ユニバーシテッド（ユニバーシティー オフ コペンハーゲン） 免疫応答のプライミング
MX2011007980A (es) 2009-02-02 2011-08-17 Okairos Ag Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas.
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
GB201321384D0 (en) * 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
JP6721145B2 (ja) 2014-07-25 2020-07-08 国立研究開発法人理化学研究所 メモリーインバリアントｎｋｔ細胞マーカー
IL271965B2 (en) * 2017-07-12 2023-03-01 Nouscom Ag Preparations containing a neoantigenic vaccine for the treatment of cancer

Also Published As

Publication number Publication date
IL274409A (en) 2020-06-30
EP3703744A1 (en) 2020-09-09
CA3078692A1 (en) 2019-05-09
NZ763337A (en) 2025-02-28
RU2020115109A3 (es) 2021-12-03
JP2023089103A (ja) 2023-06-27
US11912743B2 (en) 2024-02-27
US20210363201A1 (en) 2021-11-25
SG11202003799RA (en) 2020-05-28
KR20200076696A (ko) 2020-06-29
AU2018358019B2 (en) 2023-05-11
CN111670046B (zh) 2024-11-08
RU2020115109A (ru) 2021-12-03
WO2019086615A1 (en) 2019-05-09
KR102747530B1 (ko) 2024-12-27
BR112020008308A2 (pt) 2020-11-17
CN111670046A (zh) 2020-09-15
JP7485422B2 (ja) 2024-05-16
IL274409B1 (en) 2023-07-01
JP7386537B2 (ja) 2023-11-27
IL274409B2 (en) 2023-11-01
AU2018358019A1 (en) 2020-04-23
JP2021502076A (ja) 2021-01-28

Similar Documents

Publication Publication Date Title
MX2020004552A (es) Vacuna potenciadora de celulas t.
CL2023002252A1 (es) Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista
MX2021011687A (es) Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas.
CO2019010503A2 (es) Plataforma de identificación de péptidos inmunogénicos personalizada
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
AR134186A2 (es) Un anticuerpo anti-csf-1r, un proceso para producirlo, una composición farmacéutica que lo comprende, una secuencia de adn aislado, un vector de expresión o clonación y una célula hospedadora
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
MX2022000012A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
MX2016016533A (es) Combinaciones inmunogenas.
CO2022003702A2 (es) Vacunas para vhb y métodos de tratamiento de vhb
MX2021004425A (es) Vacuna contra cancer de cadena invariante de teleosteo.
NI201700018A (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
JO3600B1 (ar) لقاحات مؤتلفة ل fmdv و استخداماتها
CR20170079A (es) Agentes de unión a cd123 y usos de estos
CL2015001900A1 (es) Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina.
MX2017011246A (es) Composiciones a base de listeria que comprenden un sistema de expresion de minigen peptidico y metodos de uso de estas.
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
MX2023001540A (es) Vacunas contra el cancer y metodos de tratamiento que las utilizan.
CO2018001985A2 (es) Polipéptidos mrka, anticuerpos y usos de los mismos
AR095199A1 (es) Anticuerpos anti-cd52
MX2018006347A (es) Proteinas de fusion fmdv y e2 y usos de ellos.
CL2019000019A1 (es) Anticuerpos con baja inmunogenicidad y uso de los mismos